Education
About Us
Working with TipRanks
Follow Us
Charles River Laboratories Intl (CRL)
NYSE:CRL
CRL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$91.86 - $230.02
Previous CloseN/A
Volume179.29K
Average Volume (3M)948.93K
Market Cap
$7.80B
Enterprise Value$10.05B
Total Cash (Recent Filing)$182.82M
Total Debt (Recent Filing)$2.79B
Price to Earnings (P/E)449.9
Beta0.74
Next Earnings
Oct 29, 2025EPS Estimate
2.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.12
Shares Outstanding49,214,176
10 Day Avg. Volume992,028
30 Day Avg. Volume948,934
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.29
Enterprise Value/Revenue2.49
Enterprise Value/Gross Profit7.68
Enterprise Value/Ebitda19.02
Forecast
1Y Price Target
$172.00Price Target Upside11.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCharles River reported second-quarter results that included a strong beat on the top and bottom lines, driven by better-than-expected performance across all segments.
Preclinical DemandThe company is focusing on preclinical demand trends, which indicates a strategic approach to maintaining growth.
Strategic ReviewActivist participation is likely to lead to a strategic review that could enhance the company's focus on its core DSA and RMS businesses.
Bears Say
Bookings And Revenue GrowthThe main driver was the company’s weaker-than-expected DSA bookings, which declined 18% sequentially due primarily to a slowdown in demand from global biopharma clients and increased cancellations from both large pharma and smaller innovators.
DSA Segment PerformanceElevated cancelations in the DSA segment have contributed to share pressure.
Macro PressureDSA/RMS are exposed to macro pressure and FDA's animal testing plans.
Charles River Labs News
CRL FAQ
What was Charles River Laboratories Intl’s price range in the past 12 months?
Charles River Laboratories Intl lowest stock price was $91.86 and its highest was $230.02 in the past 12 months.
What is Charles River Laboratories Intl’s market cap?
Charles River Laboratories Intl’s market cap is $7.80B.
When is Charles River Laboratories Intl’s upcoming earnings report date?
Charles River Laboratories Intl’s upcoming earnings report date is Oct 29, 2025 which is in 67 days.
How were Charles River Laboratories Intl’s earnings last quarter?
Charles River Laboratories Intl released its earnings results on Aug 06, 2025. The company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.502 by $0.618.
Is Charles River Laboratories Intl overvalued?
According to Wall Street analysts Charles River Laboratories Intl’s price is currently Undervalued.
Does Charles River Laboratories Intl pay dividends?
Charles River Laboratories Intl does not currently pay dividends.
What is Charles River Laboratories Intl’s EPS estimate?
Charles River Laboratories Intl’s EPS estimate is 2.34.
How many shares outstanding does Charles River Laboratories Intl have?
Charles River Laboratories Intl has 49,214,176 shares outstanding.
What happened to Charles River Laboratories Intl’s price movement after its last earnings report?
Charles River Laboratories Intl reported an EPS of $3.12 in its last earnings report, beating expectations of $2.502. Following the earnings report the stock price went down -10.245%.
Which hedge fund is a major shareholder of Charles River Laboratories Intl?
Currently, no hedge funds are holding shares in CRL
Charles River Labs Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$172.00 (11.30% Upside)
$172.00 (11.30% Upside)
Blogger Sentiment
Bullish
CRL Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 499.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $186.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-24.38%
12-Months-Change
Fundamentals
Return on Equity
-1.96%
Trailing 12-Months
Asset Growth
-4.88%
Trailing 12-Months
Company Description
Charles River Laboratories Intl
Charles River Laboratories (CRL) is a leading global provider of laboratory services and products for the pharmaceutical and biotechnology industries. The company specializes in early-stage drug development, offering a comprehensive suite of services including preclinical and clinical research, toxicology testing, and laboratory animal medicine. With a focus on accelerating the drug development process, CRL supports its clients through a range of solutions that integrate scientific expertise and innovative technologies.
CRL Company Deck
CRL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted a solid financial performance with increased revenue and earnings per share, driven by operational improvements and favorable FX rates. The DSA segment showed signs of stabilization, but challenges remain with decreased DSA revenue and increased cancellations. The CDMO segment faced a revenue headwind due to the end of a commercial relationship. Despite these challenges, the company's strategic review and cost reductions are on track to deliver significant savings. Overall, the sentiment reflects a cautious optimism with signs of stabilization but ongoing challenges.View all CRL earnings summariesCRL Revenue Breakdown
60.53% DSA
20.48% RMS
19.00% Manufacturing
CRL Stock 12 Month Forecast
Average Price Target
$172.00
▲(11.30% Upside)
Technical Analysis
Ownership Overview
1.08% Insiders
32.90% Mutual Funds
23.94% Other Institutional Investors
15.91% Public Companies and
Individual Investors